Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation. / Larsen, Claus Morten; Faulenbach, Mirjam; Vaag, Allan; Vølund, Aage; Ehses, Jan; Seifert, Burkhardt; Mandrup-Poulsen, Thomas; Donath, Marc.
In: Ugeskrift for læger, Vol. 169, No. 45, 2007, p. 3868-71.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.
AU - Larsen, Claus Morten
AU - Faulenbach, Mirjam
AU - Vaag, Allan
AU - Vølund, Aage
AU - Ehses, Jan
AU - Seifert, Burkhardt
AU - Mandrup-Poulsen, Thomas
AU - Donath, Marc
PY - 2007
Y1 - 2007
N2 - Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5
AB - Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5
M3 - Tidsskriftartikel
C2 - 18031661
VL - 169
SP - 3868
EP - 3871
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 45
ER -
ID: 8465591